Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312510179509/d10q.htm
October 2010
July 2010
June 2010
May 2010
March 2010
February 2010
January 2010
December 2009
November 2009
August 2009
Exhibit 99.1
11755 Wilshire Blvd., 20th Floor
Los Angeles, CA 90025
News Release
ABRAXIS BIOSCIENCE REPORTS
FIRST QUARTER 2010 FINANCIAL RESULTS
| ABRAXANE® First Quarter 2010 Revenue Grows 25% to $88 Million Compared to the First Quarter of 2009 |
| Company Reports First Quarter 2010 Net Loss for Common Shareholders of $3 Million, or $0.07 Per Share, with Adjusted Net Income of $9 Million, or $0.22 Per Share |
LOS ANGELES, Calif. May 6, 2010 Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.
First Quarter 2010 Highlights
Net revenue for the first quarter of 2010 was $110.8 million compared with $72.6 million for the first quarter of 2009. ABRAXANE® revenue for the first quarter of 2010 increased to $87.9 million compared with $70.1 million for the first quarter of 2009. Other product revenue and other revenue for the first quarter of 2010 increased to $22.9 million from $2.5 million in the first quarter of last year, primarily due to increased sales of raw material products and sales from Drug Source Company, LLC, an entity in which we obtained a controlling interest during the first quarter of 2010 and whose results of operations are now required to be consolidated into our financial statements.
Gross profit for the first quarter of 2010 was $88.2 million, or 80 percent of net revenue, compared with $63.5 million, or 87 percent of net revenue, for the first quarter of 2009. While gross profit increased due to higher sales volumes in the United States as well as increased net selling prices globally, the decrease in gross margin as a percentage of net revenue was caused primarily by an increase in sales of lower margin raw material products.
(more)
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1409012/000119312510179509/d10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Abraxis Bioscience, Inc..
Abraxis Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2010 10-K Annual Report includes:
CIK: 1409012
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-10-179509
Submitted to the SEC: Thu Aug 05 2010 4:55:53 PM EST
Accepted by the SEC: Thu Aug 05 2010
Period: Wednesday, June 30, 2010
Industry: Pharmaceutical Preparations